Imuntech Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 4 Year, 1 Month
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 61.77%
- Profit Growth -2621.59%
- Ebitda 308.88%
- Net Worth -9.77%
- Total Assets 11.28%
About Imuntech Life Sciences
Imuntech Life Sciences Private Limited (ILSPL) is a Private Limited Indian Non-Government Company incorporated in India on 24 December 2020 (Four years and one month 14 days old ). Its registered office is in Allahabad, Uttar Pradesh, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Arun Kumar, Sushant Kumar, and Gunjana Arun serve as directors at the Company.
Company Details
-
Location
Allahabad, Uttar Pradesh, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U51909UP2020PTC139662
-
Company No.
139662
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
24 Dec 2020
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Kanpur
Industry
Who are the key members and board of directors at Imuntech Life Sciences?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Kumar
|
Managing Director | 24-Dec-2020 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Sushant Kumar
|
Director | 24-Dec-2020 | Current |
|
Gunjana Arun
|
Director | 24-Dec-2020 | Current |
Financial Performance of Imuntech Life Sciences.
Imuntech Life Sciences Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 61.77% increase. The company also saw a substantial fall in profitability, with a 2621.59% decrease in profit. The company's net worth dipped by a decrease of 9.77%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Imuntech Life Sciences?
Unlock access to Imuntech Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Imuntech Life Sciences?
Imuntech Life Sciences has a workforce of 0 employees as of Apr 09, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Imuntech Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Imuntech Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.